Abstract
A series of 3-benzyloxyhydantoin derivatives were designed and synthesized by introducing hydroxyurea pharmacophore into hydantoin rigid scaffold. The cytotoxic activities of the target compounds were evaluated in vitro against three cancer cell lines. Compounds 5b, 5c, 5e, 5g, 6c and 6g displayed high activity on all of the three cancer cell lines and the most promising compounds were 5g, 6g with IC50 values of 0.04 and 0.01µM. Binding of derivatives for the ribonucleotide reductase (RR) was investigated by use of molecular docking studies. Our findings show that modification at the C5 position of hydantoin with isopropyl or isobutyl was favorable to increasing binding affinity to the active site of the RR receptor and antiproliferative activity.
Keywords: Molecular modeling, ribonucleotide reductase, anticancer, synthesis, MTT Assay, benzyloxyhydantoin derivatives.
Medicinal Chemistry
Title:Synthesis, Anticancer Evaluation and Docking Study of 3- Benzyloxyhydantoin Derivatives
Volume: 12 Issue: 1
Author(s): Jun Liu, Kai Zhang, Xi Mai, Jinjin Wei, Yijing Liao, Ying Zhong, Yang Liu, Lihua Feng and Chao Liu
Affiliation:
Keywords: Molecular modeling, ribonucleotide reductase, anticancer, synthesis, MTT Assay, benzyloxyhydantoin derivatives.
Abstract: A series of 3-benzyloxyhydantoin derivatives were designed and synthesized by introducing hydroxyurea pharmacophore into hydantoin rigid scaffold. The cytotoxic activities of the target compounds were evaluated in vitro against three cancer cell lines. Compounds 5b, 5c, 5e, 5g, 6c and 6g displayed high activity on all of the three cancer cell lines and the most promising compounds were 5g, 6g with IC50 values of 0.04 and 0.01µM. Binding of derivatives for the ribonucleotide reductase (RR) was investigated by use of molecular docking studies. Our findings show that modification at the C5 position of hydantoin with isopropyl or isobutyl was favorable to increasing binding affinity to the active site of the RR receptor and antiproliferative activity.
Export Options
About this article
Cite this article as:
Liu Jun, Zhang Kai, Mai Xi, Wei Jinjin, Liao Yijing, Zhong Ying, Liu Yang, Feng Lihua and Liu Chao, Synthesis, Anticancer Evaluation and Docking Study of 3- Benzyloxyhydantoin Derivatives, Medicinal Chemistry 2016; 12 (1) . https://dx.doi.org/10.2174/1573406411666150708111631
DOI https://dx.doi.org/10.2174/1573406411666150708111631 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Medical Perspective of Childhood Marriage in Nigeria: Body of Evidence from 2013 Nigeria Demographic and Health Survey
Current Women`s Health Reviews Current and Future Drugs for Appetite Regulation and Obesity Treatment
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Pharmaceutical Measures to Prevent Doxorubicin-Induced Cardiotoxicity
Mini-Reviews in Medicinal Chemistry The Role of Physical Exercise and Omega-3 Fatty Acids in Depressive Illness in the Elderly
Current Neuropharmacology The Role of FLT3 Kinase as an AML Therapy Target
Current Pharmaceutical Design Meet Our Regional Editor
Current Organic Chemistry Targeting Histone Deacetylases in Neuroblastoma
Current Pharmaceutical Design Association of Viruses in the Development of Cardiovascular Diseases
Current Pharmaceutical Design Vasoactive Intestinal Peptide Receptors: A Molecular Target in Breast and Lung Cancer
Current Pharmaceutical Design Antidepressants: Update on Benefits and Risks
Current Psychopharmacology Von Hippel-Lindau Disease
Current Molecular Medicine Recent Patents Reveal Microtubules as Persistent Promising Target for Novel Drug Development for Cancers
Recent Patents on Anti-Infective Drug Discovery Recent Advances in Molecular Image-Guided Cancer Radionuclide Therapy
Current Drug Targets Haploidentical Stem Cell Transplantation in Childhood
Current Cancer Therapy Reviews Blockers of Voltage-Gated Sodium Channels for the Treatment of Central Nervous System Diseases
Recent Patents on CNS Drug Discovery (Discontinued) Reactive Oxygen Species in the Initiation of IL-4 Driven Autoimmunity as a Potential Therapeutic Target
Current Pharmaceutical Design Voluntary Medical Male Circumcision among Rwanda Defense Force Members
Current HIV Research Subject Index To Volume 2
Current Nutrition & Food Science Advantages of Structure-Based Drug Design Approaches in Neurological Disorders
Current Neuropharmacology Flavonoids on Allergy
Current Pharmaceutical Design